Article

SARcode reports phase III results for lifitegrast

SARcode Bioscience Inc. announced the topline results from OPUS-1, a pivotal phase III study of lifitegrast ophthalmic solution 5.0% for the treatment of dry eye disease.

Related Videos
Ophthalmology Times: Kathryn Colby, MD, PhD, reflects on National Women Physicians Day
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Related Content
(Image credit: AdobeStock/Pisahouse)
February 5th 2025

Case studies highlight advanced techniques in glaucoma management

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Researchers investigate how COVID-19 affects retinal microvascular structure
February 5th 2025

Researchers investigate how COVID-19 affects retinal microvascular structure

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

FDA approves continuous delivery ranibizumab injection (Susvimo) for the treatment of diabetic macular edema
February 4th 2025

FDA approves continuous delivery ranibizumab injection (Susvimo) for the treatment of diabetic macular edema

Study investigates neurological impact of diabetic vitreous hemorrhage
February 4th 2025

Study investigates neurological impact of diabetic vitreous hemorrhage

© 2025 MJH Life Sciences

All rights reserved.